Financial Data and Key Metrics Changes - Cash, cash equivalents, and restricted cash equivalents as of December 31, 2025, were approximately $37 million, with total grant funds remaining from the NIA at $35.7 million [17] - Research and development expenses were $37.2 million for the year ended December 31, 2025, compared to $41.7 million for 2024, reflecting a decrease due to the completion of clinical trials [18] - General and administrative expenses were $10.6 million for the year ended December 31, 2025, down from $12.3 million in 2024, primarily due to reduced stock-based compensation [18] - The company reported a net loss of $23.5 million, or $0.32 per basic and diluted share for the year ended December 31, 2025, compared to a net loss of $34 million or $0.86 per share for 2024 [18][19] Business Line Data and Key Metrics Changes - The company has prioritized the development of zervimesine for the treatment of DLB psychosis, following positive results from the phase II SHIMMER study, which showed an 86% slowing of progression in neuropsychiatric symptoms compared to placebo [5][10] - Zervimesine is also being studied in a phase II trial called START for patients with mild cognitive impairment or early Alzheimer's disease, with top-line results expected in 2027 [15][16] Market Data and Key Metrics Changes - The prevalence of psychosis in DLB patients is significant, with as many as 80% experiencing such symptoms, highlighting a substantial unmet medical need in this market [8] - The company aims to expedite the path to market for zervimesine by focusing on DLB psychosis, which is currently unaddressed by any approved medications [48] Company Strategy and Development Direction - The company is focusing on zervimesine's potential as a first-in-class treatment option for DLB patients with psychosis, leveraging positive feedback from both clinical trials and an expanded access program [12][48] - The strategy includes engaging with the FDA's Division of Psychiatry to define a path towards registration for zervimesine [6][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the regulatory path for zervimesine, particularly in addressing psychosis in DLB, and noted the compelling data from the SHIMMER trial [6][25] - The company is committed to developing zervimesine for Alzheimer's disease while prioritizing DLB psychosis due to the strong data observed [30] Other Important Information - The company has funding to continue the expanded access program for zervimesine for another nine to twelve months, indicating strong interest from patients and families [12] - Anecdotal feedback from the expanded access program has been overwhelmingly positive, reinforcing the company's commitment to completing development work for zervimesine [13] Q&A Session Summary Question: Plans for further exploration with zervimesine in ocular conditions - The company is currently focused on developing zervimesine for DLB and is not considering an ophthalmology program at this time [20] Question: Regulatory path for DLB program and trial details - The company intends to develop zervimesine for a label relating to psychosis in DLB and is working on defining the outcome measures with the FDA [25][26] Question: Updates on additional trials and studies - The company is completing low-risk studies related to pharmacology and formulation changes, which are expected to be finished in 2026 [27] Question: Effect of zervimesine on behavioral domains in Alzheimer's disease - The company plans to see the results of the START trial before prioritizing further development in Alzheimer's disease [30] Question: Alignment with EMA for DLB psychosis trial - The company will seek alignment with the EMA after receiving feedback from the FDA regarding the DLB psychosis trial [32] Question: Synergy with existing CNS medications - The company has conducted studies on standard care background medications and is collecting data on potential benefits of using zervimesine in combination with other drugs [35][36] Question: Mechanism of action of zervimesine on psychosis - The company believes zervimesine interrupts the basic pathophysiology of the disease rather than directly impacting receptors responsible for psychosis [41][42] Question: Primary and secondary endpoints for the proposed DLB psychosis trial - The company has not finalized the study design but intends to include secondary measures related to cognition and other functions [44]

Core Insights - ProMIS Neurosciences has completed enrollment for its PRECISE-AD Phase 1b trial, with 144 patients enrolled, exceeding the target of 128, indicating strong interest in PMN310's therapeutic potential [3][8] - The company reported a net loss of $39.7 million for the year ended December 31, 2025, with cash reserves of $6.1 million, reflecting its investment in advancing the PRECISE-AD trial [12][24] - PMN310 has shown a favorable safety profile with no treatment-related serious adverse events reported to date, and it is designed to minimize treatment-related side effects, particularly Amyloid-Related Imaging Abnormalities (ARIA) [4][15] Clinical Development - The PRECISE-AD trial is expected to complete six-month assessments in Q2 2026, with a blinded interim analysis anticipated in early Q3 2026 and top-line data expected in early 2027 [1][9] - PMN310 has been granted Fast Track Designation by the FDA, which may facilitate its development and regulatory engagement [7][15] - The company is also developing a subcutaneous formulation of PMN310 to improve patient experience and strengthen its competitive profile [6][13] Financial Overview - The company closed a financing round in early 2026, raising up to $175 million, which includes $75 million upfront and $100 million tied to future warrant exercises, providing a cash runway through 2027 [6][12] - Research and development expenses for 2025 were $33.4 million, significantly higher than the $10.6 million in 2024, primarily due to costs associated with the PRECISE-AD trial [12][24] - General and administrative expenses increased to $6.8 million in 2025 from $6.2 million in 2024, driven by a moderate increase in employee headcount [12][24] Pipeline and Future Directions - PMN267 and PMN442 are other key pipeline candidates targeting amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), respectively, with PMN267 showing selectivity for pathogenic TDP-43 and PMN442 targeting alpha-synuclein [13][14] - The company is monitoring developments in preclinical and asymptomatic Alzheimer's disease trials, considering potential expansion into these areas based on PMN310's safety profile [8]

CervoMed FY Conference Summary Company Overview - **Company**: CervoMed (NasdaqCM:CRVO) - **Focus**: Development of oral drugs for neurodegenerative diseases, including dementia with Lewy bodies (DLB), ALS, and frontotemporal dementia (FTD) [1][2] Industry Insights - **Dementia with Lewy Bodies (DLB)**: - DLB is the second most common progressive dementia after Alzheimer's disease, affecting over 700,000 individuals in the U.S. [8] - Current treatments are limited to symptomatic therapies, with no approved therapies in the U.S. or EU [9] - DLB progresses faster than Alzheimer's, with a typical timeline from diagnosis to nursing home care being around two years [10] - Diagnosis of DLB is challenging, with only about 50% of patients receiving a clinical diagnosis [13] Core Product: Neflamapimod - **Mechanism of Action**: Neflamapimod is a p38 alpha inhibitor, designed to treat synaptic dysfunction associated with DLB [15][18] - **Clinical Data**: - Positive results from Phase IIa study showed improvements in cognitive function and biomarkers of neurodegeneration [24] - Phase IIb study faced challenges due to manufacturing issues but later batches showed significant clinical efficacy [27] - The upcoming Phase III study will involve 300 patients over 32 weeks, focusing on CDR Sum of Boxes as the primary endpoint [28] Clinical Development and Regulatory Engagement - **FDA Engagement**: CervoMed received alignment from the FDA on the design of the Phase III study and potential registration path [28] - **Patient Enrollment Strategy**: Focus on DLB patients without Alzheimer's co-pathology to enhance clinical efficacy [30] - **Dose Confirmation**: The confirmed dose for Phase III will be 50 mg TID, increased from 40 mg in Phase IIb to ensure adequate plasma concentrations [32] Market Potential - **Patient Population**: Estimated 360,000 DLB patients without Alzheimer's co-pathology in the U.S., with significant markets in Europe and Asia [42] - **Commercial Opportunity**: The focus on precision medicine and biomarker-driven patient selection is expected to enhance the drug's marketability and align with payer expectations for value-based pricing [43] Key Milestones and Future Programs - **Upcoming Clinical Data**: Additional programs in recovery after stroke and primary progressive aphasia are expected to yield clinical or biomarker data by mid-year [61][62] - **Recognition**: CervoMed has been selected for the ExPALS program, which supports promising new therapies in ALS, further validating its scientific approach [62] Conclusion - CervoMed is positioned to address significant unmet needs in the neurodegenerative disease space, particularly with its lead asset, neflamapimod, which shows promise in treating DLB and potentially other conditions. The company is on track for a pivotal Phase III study and has a robust pipeline of additional programs.

Core Insights - Amylyx Pharmaceuticals, Inc. is focused on developing treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, with its main product AMX0035 being a dual UPR-Bax apoptosis inhibitor [1] - The consensus price target for Amylyx has increased from $19.14 to $23.50 over the past year, reflecting growing optimism among analysts regarding the company's future [2][5] - Wall Street analysts project a 29.3% upside for the stock, indicating strong consensus in raising earnings estimates and potential growth for Amylyx [3] Company Developments - The recent Q3 2025 earnings call featured participation from prominent analysts from major financial institutions, highlighting the significance of Amylyx's developments [3][5] - Investors are encouraged to monitor updates on clinical trials and regulatory progress, as these factors could influence the stock's target price and overall market performance [4] Market Context - The biopharmaceutical sector is increasingly interested in neurodegenerative diseases, which may shape the future prospects of Amylyx Pharmaceuticals [4]

Core Viewpoint - CervoMed Inc. has announced that its investigational drug neflamapimod has been included in the EXPERTS-ALS platform for rapid testing in amyotrophic lateral sclerosis (ALS), with the first patient expected to be dosed by the end of 2026 [1][4] Group 1: Neflamapimod and Its Mechanism - Neflamapimod is an oral small molecule drug candidate that targets critical disease processes underlying neurodegenerative disorders by selectively inhibiting p38 MAP kinase, a key driver of neuroinflammation [6][11] - The drug has shown positive clinical activity in dementia with Lewy bodies, demonstrating a potent effect on blood biomarkers of neurodegeneration [3][8] - Neflamapimod is currently in clinical development for multiple indications, including dementia with Lewy bodies, recovery after ischemic stroke, and primary progressive aphasia [7][11] Group 2: EXPERTS-ALS Platform - EXPERTS-ALS is a UK-based platform designed to rapidly evaluate potential therapies for ALS through a randomized, multicenter trial that measures neurofilament light chain (NfL) levels, which correlate with disease progression [2][9] - The initial evaluation of neflamapimod will involve approximately 35 ALS participants over 18-24 weeks, with the potential to expand to a total of 80 patients [2] - The platform is funded by the UK National Institute for Health and Care Research and supported by various motor neuron disease charities [2][9] Group 3: Clinical Trial Insights - Previous clinical trials of neflamapimod have involved over 800 participants, showing it to be generally well tolerated and effective in improving dementia severity and functional mobility in patients with dementia with Lewy bodies [8] - The Phase 2a AscenD-LB trial and Phase 2b RewinD-LB trial provided evidence of neflamapimod's potential clinical benefits, particularly in patients without Alzheimer's disease co-pathology [8] Group 4: ALS Overview - Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting approximately 168,000 people worldwide, with no approved therapies to stop or reverse its progression [5]

Core Insights - Harness Therapeutics has nominated HRN001 as its lead drug candidate for Huntington's disease, aiming for first-in-human studies in 2027 [1][5] - The company has formed a Clinical Advisory Board (CAB) to provide strategic guidance for the clinical development of HRN001 [6][8] - Dr. Andy Billinton, the Chief Scientific Officer, will present preclinical data at the CHDI Foundation Huntington's Disease Therapeutics Conference [7] Company Overview - Harness Therapeutics is a biotechnology company focused on addressing previously undruggable targets to transform treatments for neurodegenerative diseases [20] - The company utilizes its proprietary MISBA® platform technology to enable precise upregulation of target protein levels, which is crucial for developing disease-modifying therapies [20][21] - The company is based in Cambridge, UK, and has attracted leading life science investors, including Takeda Ventures and SV Health Investors' Dementia Discovery Fund [22] Product Development - HRN001 is an antisense oligonucleotide designed to upregulate FAN1, a key DNA repair nuclease, which has shown promise in slowing somatic expansion in Huntington's disease models [4][5] - Preclinical development of HRN001 will continue throughout 2026, with the goal of supporting clinical entry in 2027 [5] - The MISBA® platform is also being explored for other triplet repeat disorders and a broader pipeline of neurodegenerative diseases [5] Clinical Advisory Board - The CAB consists of leading experts in Huntington's disease, including Dr. Irina Antonijevic, Dr. Anne Rosser, and Dr. Jeffrey Long, among others [9][10] - The CAB will provide strategic guidance on clinical development, trial design, and translational strategy as the program advances [6][10] Scientific Rationale - Huntington's disease is caused by the expansion of CAG repeats in the huntingtin gene, with ongoing somatic expansion recognized as a key driver of disease progression [2][3] - FAN1 has emerged as a compelling target for suppressing somatic expansion, demonstrating a strong genetic association with disease onset [3][10]

Hangzhou Highlightll Pharmaceutical Co., Ltd. 杭州高光製藥股份有限公司 (A joint stock company established in the People's Republic of China with limited liability) WARNING The publication of this Application Proof is required by The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and the Securities and Futures Commission (the "Commission") solely for the purpose of providing information to the public in Hong Kong. This Application Proof is in draft form. The information contained in it is incomplete and is s ...

Core Insights - Annovis Bio, Inc. is set to present at the 2025 Annual Meeting of the Parkinson Study Group, showcasing its advancements in therapies for neurodegenerative diseases like Alzheimer's and Parkinson's [1][5] Group 1: Presentation Highlights - The presentation will build on recent Phase 3 PD biomarker data, indicating that patients with amyloid co-pathology show significant cognitive decline, which is counteracted and reversed by the drug buntanetap [2] - A cross-study comparison of completed trials will be introduced, providing a comprehensive overview of cognitive outcomes across all tested indications, particularly highlighting the benefits for patients with amyloid pathology [3] - Findings suggest that individuals with biomarker-confirmed amyloid presence experience the greatest cognitive gains following treatment with buntanetap, validating the drug's mechanism as a translational inhibitor of neurotoxic aggregating proteins [3] Group 2: Company Overview - Annovis Bio is headquartered in Malvern, Pennsylvania, and focuses on developing innovative therapies aimed at improving outcomes and quality of life for patients suffering from neurodegenerative diseases [6] - The company is committed to advancing research and showcasing best practices in the field of Parkinson's disease [5]

Core Insights - Annovis Bio, Inc. announced new results indicating that its drug candidate, buntanetap, can reduce inflammation and improve cellular health in Alzheimer's patients, suggesting potential disease-modifying effects beyond just symptomatic relief [1][2]. Group 1: Clinical Study Results - The Phase 2/3 study analysis showed that buntanetap effectively targets key biomarkers of neuroinflammation and neurodegeneration, leading to reductions in inflammatory markers such as IL-5, IL-6, S100A12, IFN-γ, and IGF1R compared to placebo [2]. - Buntanetap also decreased levels of neurofilament light chain (NFL), a marker of neuronal damage, indicating improved cellular integrity and neuronal health, particularly in patients with positive pTau217 plasma levels [2][3]. Group 2: Mechanism and Therapeutic Potential - The drug's ability to target multiple neurotoxic proteins simultaneously is highlighted as a significant advantage, potentially interrupting the toxic cascade associated with Alzheimer's disease [3]. - Previous clinical benefits were noted in mild Alzheimer's patients, who experienced significant cognitive improvements, reinforcing the potential of buntanetap as a disease-modifying therapy [3]. Group 3: Ongoing Research and Future Outlook - Buntanetap is currently undergoing a pivotal Phase 3 trial in early Alzheimer's disease, with a 6-month readout focused on symptomatic improvement and an 18-month readout aimed at assessing disease modification [3][4]. - The full biomarker data will be presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in December 2025, which is expected to provide further insights into the drug's efficacy [4].

Summary of Elektor's Conference Call Company Overview - **Company**: Elektor - **Focus**: Development of disease-modifying therapies for neurodegenerative diseases, including Alzheimer's and frontotemporal dementia (FTD) [6][7] Key Industry Insights - **Neurodegenerative Diseases**: Elektor is addressing urgent unmet needs in neurodegenerative diseases through an integrated biotech approach combining genetics, immunology, and neuroscience [6] - **Progranulin Elevating Franchise**: The company is developing therapies targeting progranulin levels to treat FTD caused by granulin mutations and Alzheimer's disease [9][10] Core Points and Arguments - **Pipeline Overview**: Elektor has a multistage pipeline with late-stage programs, including: - **Latazimumab**: For FTD GRN, received breakthrough therapy and orphan drug designations, with phase three data expected by mid-Q4 2025 [7][22] - **Nivisibart (formerly AL101)**: For Alzheimer's disease, fully enrolled in a phase two trial [8][25] - **ABC Technology**: The proprietary electro brain carrier (ABC) technology enhances drug delivery across the blood-brain barrier, improving therapeutic efficacy [7][27] - **Clinical Data**: In the INFRANT2 phase two study, Latazimumab demonstrated a 48% slowing of clinical progression in symptomatic FTD GRN patients compared to matched historical controls [22] - **Economic Burden**: The economic burden per patient for FTD is nearly double that of Alzheimer's, highlighting the urgency for effective therapies [11] Additional Important Content - **Genetic Testing**: Increased uptake of genetic testing is anticipated as disease-specific treatments become available, which could shift the diagnostic landscape for FTD GRN [12] - **Partnership with GSK**: The collaboration includes significant financial commitments, with $700 million in upfront payments and potential milestones totaling $1.5 billion [26] - **Future Programs**: Elektor is developing additional therapies, including: - **Anti-amyloid beta antibodies**: Targeting Alzheimer's disease with two candidates, AL037 and AL137, showing promising preclinical results [46][45] - **Enzyme replacement therapy for Parkinson's disease**: Targeting GBA mutations with engineered GK's enzyme [47][50] - **siRNA programs**: Targeting tau, alpha-synuclein, and NLRP for various neurodegenerative diseases [76][77] Financial Position - **Cash Resources**: Elektor has over $300 million in demand to support ongoing and future programs [82] Conclusion - Elektor is positioned to make significant advancements in the treatment of neurodegenerative diseases through its innovative therapies and technologies, with multiple catalysts expected in the near future [82]